The US Food and Drug Administration has granted breakthrough therapy designation to an EGFR tyrosine kinase inhibitor for the first-line treatment of EGFR-positive non-small cell lung cancer. READ MORE
First-line treatment with alectinib prolonged progression-free survival with less toxicity compared with crizotinib in patients with ALK-positive non-small-cell lung cancer.
The US FDA has granted accelerated approval to a treatment for patients with a type of lung cancer who have progressed on initial therapy.
Research in Review
Patients with advanced non-small cell lung cancer who receive previous radiotherapy are more likely to benefit from immunotherapy than those patients without previous radiotherapy.
Adjuvant treatment with the targeted therapy gefitinib significantly improved disease-free survival over standard of care after surgery for patients with non–small cell lung cancer, according to research that will be presented at the 2017 ASCO Annual Meeting.
Selecting patients with cyclooxygenase-2 expression by immunohistochemistry fails to improve survival outcomes in non-small cell lung cancer.
Patients with ALK-rearranged non-small cell lung cancer who are treated with crizotinib may experience increased progression-free survival with a decrease in a type of circulating tumor cells.